Compare Inovio Pharmaceuticals Inc (INO) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs PPG Industries, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.75 (market cap $78.55M), while PPG Industries, Inc. trades at $114.56 (market cap $25.82B). The key difference: PPG Industries, Inc. is far larger — about 328.7× Inovio Pharmaceuticals Inc's market cap, and PPG Industries, Inc. pays a 2.55% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PPG | |
|---|---|---|
Market Cap | $78.55M | $25.82B |
Sector | Health | Basic Materials |
52-Week High | $2.87 | $131.56 |
52-Week Low | $0.66 | $94.34 |
Enterprise Value | $49.56M | $31.69B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
PPG Industries trades at $115.47, down 3.55% amid bearish technical signals, though fundamentals show resilience with Q2 2026 sales up 7% year-over-year and a 4.2% dividend hike in July 2026. The stock's valuation appears reasonable with a P/E of 16.67 and P/S of 1.59, while profitability metrics like a 9.57% net margin and 19.63% ROE support operational strength. Recent leadership changes in Industrial Coatings and FTSE4Good recognition highlight ongoing corporate developments.
Wall Street maintains a bullish stance with 55% buy ratings and a $129.17 consensus target, implying 12% upside, but near-term risks include raw material cost pressures and mixed earnings performance. The technical bearish signal and proximity to support at $114 suggest cautious entry points, while the dividend aristocrat status and solid cash flow provide downside protection for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
